Information for healthcare professionals - Targeted deployment of COVID-19 medicines for non-hospitalised patients

Changes have been made to the UK-wide clinical commissioning policy to reflect both the current understanding on the likely impact of the Omicron variant on the efficacy of the combination nMAB casirivumab and imdevimab and the availability of the nMAB sotrovimab (from the week commencing 20 December)

Further information on the updated policy and actions can be found in the CMO letter.